{"title":"阿尔茨海默病发病机制中的小胶质细胞 PTK2B/Pyk2","authors":"Yun Guo, Cheng-Kun Sun, Lian Tang, Meng-Shan Tan","doi":"10.2174/0115672050299004240129051655","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a highly hereditary disease with complex genetic susceptibility factors. Extensive genome-wide association studies have established a distinct susceptibility link between the protein tyrosine kinase 2β (<i>PTK2B</i>) gene and late-onset Alzheimer's disease (LOAD), but the specific pathogenic mechanisms remain incompletely understood. <i>PTK2B</i> is known to be expressed in neurons, and recent research has revealed its more important significance in microglia. Elucidating the role of <i>PTK2B</i> high expression in microglia in AD's progression is crucial for uncovering novel pathogenic mechanisms of the disease. Our review of existing studies suggests a close relationship between <i>PTK2B</i>/proline-rich tyrosine kinase 2 (Pyk2) and tau pathology, and this process might be β-amyloid (Aβ) dependence. Pyk2 is hypothesized as a pivotal target linking Aβ and tau pathologies. Concurrently, Aβ-activated Pyk2 participates in the regulation of microglial activation and its proinflammatory functions. Consequently, it is reasonable to presume that Pyk2 in microglia contributes to amyloid-induced tau pathology in AD via a neuroinflammatory pathway. Furthermore, many things remain unclear, such as identifying the specific pathways that lead to the release of downstream inflammatory factors due to Pyk2 phosphorylation and whether all types of inflammatory factors can activate neuronal kinase pathways. Additionally, further in vivo experiments are essential to validate this hypothesized pathway. Considering <i>PTK2B</i>/Pyk2's potential role in AD pathogenesis, targeting this pathway may offer innovative and promising therapeutic approaches for AD.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"692-704"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Microglia <i>PTK2B</i>/Pyk2 in the Pathogenesis of Alzheimer's Disease.\",\"authors\":\"Yun Guo, Cheng-Kun Sun, Lian Tang, Meng-Shan Tan\",\"doi\":\"10.2174/0115672050299004240129051655\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alzheimer's disease (AD) is a highly hereditary disease with complex genetic susceptibility factors. Extensive genome-wide association studies have established a distinct susceptibility link between the protein tyrosine kinase 2β (<i>PTK2B</i>) gene and late-onset Alzheimer's disease (LOAD), but the specific pathogenic mechanisms remain incompletely understood. <i>PTK2B</i> is known to be expressed in neurons, and recent research has revealed its more important significance in microglia. Elucidating the role of <i>PTK2B</i> high expression in microglia in AD's progression is crucial for uncovering novel pathogenic mechanisms of the disease. Our review of existing studies suggests a close relationship between <i>PTK2B</i>/proline-rich tyrosine kinase 2 (Pyk2) and tau pathology, and this process might be β-amyloid (Aβ) dependence. Pyk2 is hypothesized as a pivotal target linking Aβ and tau pathologies. Concurrently, Aβ-activated Pyk2 participates in the regulation of microglial activation and its proinflammatory functions. Consequently, it is reasonable to presume that Pyk2 in microglia contributes to amyloid-induced tau pathology in AD via a neuroinflammatory pathway. Furthermore, many things remain unclear, such as identifying the specific pathways that lead to the release of downstream inflammatory factors due to Pyk2 phosphorylation and whether all types of inflammatory factors can activate neuronal kinase pathways. Additionally, further in vivo experiments are essential to validate this hypothesized pathway. Considering <i>PTK2B</i>/Pyk2's potential role in AD pathogenesis, targeting this pathway may offer innovative and promising therapeutic approaches for AD.</p>\",\"PeriodicalId\":94309,\"journal\":{\"name\":\"Current Alzheimer research\",\"volume\":\" \",\"pages\":\"692-704\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Alzheimer research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115672050299004240129051655\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Alzheimer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672050299004240129051655","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
阿尔茨海默病(AD)是一种高度遗传性疾病,遗传易感因素复杂。广泛的全基因组关联研究证实,蛋白酪氨酸激酶 2β (PTK2B)基因与晚发性阿尔茨海默病(LOAD)之间存在明显的易感性联系,但具体的致病机制仍不完全清楚。众所周知,PTK2B 在神经元中表达,最近的研究揭示了它在小胶质细胞中更重要的意义。阐明PTK2B在小胶质细胞中的高表达在AD进展中的作用对于发现该病的新致病机制至关重要。我们对现有研究的回顾表明,PTK2B/富脯氨酸酪氨酸激酶2(Pyk2)与tau病理学之间存在密切关系,而这一过程可能依赖于β-淀粉样蛋白(Aβ)。Pyk2被认为是连接Aβ和tau病理学的关键靶点。同时,Aβ激活的Pyk2参与调节小胶质细胞的活化及其促炎功能。因此,我们有理由推测,小胶质细胞中的 Pyk2 通过神经炎症途径导致了淀粉样蛋白诱导的 tau 病理学。此外,还有许多事情尚不清楚,如确定PTK2B磷酸化导致下游炎症因子释放的具体途径,以及是否所有类型的炎症因子都能激活神经元激酶通路。此外,进一步的体内实验对于验证这一假设的通路至关重要。考虑到PTK2B/Pyk2在AD发病机制中的潜在作用,靶向这一通路可能会为AD提供创新且有前景的治疗方法。
Microglia PTK2B/Pyk2 in the Pathogenesis of Alzheimer's Disease.
Alzheimer's disease (AD) is a highly hereditary disease with complex genetic susceptibility factors. Extensive genome-wide association studies have established a distinct susceptibility link between the protein tyrosine kinase 2β (PTK2B) gene and late-onset Alzheimer's disease (LOAD), but the specific pathogenic mechanisms remain incompletely understood. PTK2B is known to be expressed in neurons, and recent research has revealed its more important significance in microglia. Elucidating the role of PTK2B high expression in microglia in AD's progression is crucial for uncovering novel pathogenic mechanisms of the disease. Our review of existing studies suggests a close relationship between PTK2B/proline-rich tyrosine kinase 2 (Pyk2) and tau pathology, and this process might be β-amyloid (Aβ) dependence. Pyk2 is hypothesized as a pivotal target linking Aβ and tau pathologies. Concurrently, Aβ-activated Pyk2 participates in the regulation of microglial activation and its proinflammatory functions. Consequently, it is reasonable to presume that Pyk2 in microglia contributes to amyloid-induced tau pathology in AD via a neuroinflammatory pathway. Furthermore, many things remain unclear, such as identifying the specific pathways that lead to the release of downstream inflammatory factors due to Pyk2 phosphorylation and whether all types of inflammatory factors can activate neuronal kinase pathways. Additionally, further in vivo experiments are essential to validate this hypothesized pathway. Considering PTK2B/Pyk2's potential role in AD pathogenesis, targeting this pathway may offer innovative and promising therapeutic approaches for AD.